Clinical Trial Update: ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ABSK-011 plus best supportive care versus placebo plus BSC in previously treated advanced hepatocellular carcinoma with FGF19 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ABSK-011

Snippet

Sponsor: Abbisko Therapeutics Co, Ltd | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING